DAGM: A novel modelling framework to assess the risk of HER2-negative breast cancer based on germline rare coding mutations - Yang, Mei; Fan, Yanhui; Wu, Zhi-Yong; Gu, Jin; Feng, Zhendong; Zhang, Qiangzu; Han, Shunhua; Zhang, Zhonghai; Li, Xu; Hsueh, Yi-Ching; Ni, Yanxiang; Li, Xiaoling; et al. (EBioMedicine, 2021)
Keywords: Activity profiles of signalling pathways (APSP); Advanced Basic Science; Damage assessment of genomic mutations (DAGM); Germline rare coding mutations; HER2 signalling pathway; HER2-negative breast cancer; Immune suppression; Internal Medicine; Research Paper; Risk assessment; PR; Germline rare coding mutations; WES; CCLE; GSEA; Damage assessment of genomic mutations (DAGM); SVM; ER; PBMC; TCGA; AUC; PRS; PCC; Activity profiles of signalling pathways (APSP); Risk assessment; Immune suppression; HER2-negative breast cancer; HER2 signalling pathway; HER2; TNBC; RCM; Support Vector Machine; Progesterone receptor; Triple-negative breast cancer; human epidermal growth factor 2; polygenic risk score; Gene Set Enrichment Analysis, GWAS: genome-wide association study; peripheral blood mononuclear cells; area under the receiver operating characteristic curve; Estrogen receptor, GDF: global driving force; Cancer Cell Line Encyclopedia, DAGM: damage assessment framework of genomic mutations; The Cancer Genome Atlas; rare coding mutations; whole-exome sequencing; Pearson correlation coefficients